Related Experiment Video
Updated: Aug 1, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
[Suicide gene therapy for glioma using HSV-tk/GCV system]
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|August 2, 2000
Summary
This study establishes a suicide gene therapy system using the herpes simplex virus thymidine kinase (HSV-tk) gene and ganciclovir (GCV) for glioma treatment. The HSV-tk/GCV system effectively eradicated glioma cells both in vitro and in vivo.
Area of Science:
- Molecular Biology
- Oncology
- Gene Therapy
Context:
- Glioblastoma is a highly aggressive brain tumor with limited treatment options.
- Suicide gene therapy offers a targeted approach to cancer treatment.
Purpose:
- To develop and evaluate a herpes simplex virus thymidine kinase (HSV-tk)/ganciclovir (GCV) suicide gene therapy system for glioma.
- To assess the efficacy of this system in vitro and in vivo.
Summary:
- C6 rat glioma cells were engineered to express the HSV-tk gene, creating the C6/tk cell line.
- Growth inhibition studies confirmed GCV as the most effective prodrug, with C6/tk cells showing high sensitivity (IC50 < 0.2 μmol/L).
- In vivo studies in nude mice demonstrated significant tumor inhibition in the HSV-tk/GCV treatment group.
Impact:
- This research validates the HSV-tk/GCV system as a potent strategy for glioma eradication.
- The findings support the potential clinical application of suicide gene therapy for brain tumors.
